Washington, D.C. (July 14, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement today regarding yesterday’s passage by the House Energy and Commerce Committee of H.R. 3299, the Strengthening Public Health Emergency Response Act of 2016:
“BIO applauds yesterday’s broad, bipartisan vote by the House Energy & Commerce Committee to advance H.R. 3299, the Strengthening Public Health Emergency Response Act of 2016. If enacted, this bill would take substantial steps to address the many barriers which exist to developing medical countermeasures needed for protection against chemical, biological, radiological and nuclear (CBRN) threats as well as naturally-occurring infectious diseases such as Zika virus and pandemic influenza.
“The bill’s establishment of a Priority Review Voucher (PRV) program for material threat medical countermeasures is a particularly important provision which will help spur investment in the research and development of such products.
“We applaud Representatives Brooks and Eshoo, as well as Chairman Upton, for their leadership in advancing this vital legislation.”
About BIO
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.
Upcoming BIO Events
September 21-23, 2016 Bethesda, MD
| BIO IP & Diagnostics Symposium September 29, 2016 Alexandria, VA |
October 18-19, 2016 San Francisco, CA
| October 26-28, 2016
|
###